Studienzentrum Zehlendorf
- Address
- Teltower Damm 7, 14169 Berlin, Germany
Studienzentrum Zehlendorf - Breast Cancer Research Center
Studienzentrum Zehlendorf is a specialized clinical research facility focused on advancing treatment strategies for early-stage breast cancer. The center demonstrates particular expertise in evaluating novel adjuvant therapies designed to prevent disease recurrence in patients with hormone receptor positive breast cancer and those with genetic predispositions to the disease.
- Targeted therapy trials combining CDK4/6 inhibitors with endocrine therapy for HR+/HER2- early breast cancer
- PARP inhibitor studies for patients with germline BRCA mutations and high-risk breast cancer
- Invasive disease-free survival (iDFS) optimization in adjuvant treatment settings
The research center actively participates in large-scale international collaborative trials investigating precision medicine approaches tailored to specific molecular subtypes of breast cancer. Their clinical portfolio emphasizes both hormone receptor positive and BRCA-mutated tumors, reflecting a commitment to personalized cancer treatment strategies that target the underlying biological mechanisms of disease progression and recurrence.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Studienzentrum Zehlendorf
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study | AstraZeneca AB | Phase III | Not Recruiting | Aug 2014 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Olaparib | 1 | Unknown | 2014-08-01 | 2014-08-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.